<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00316940</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000479712</org_study_id>
    <secondary_id>ONCOTHER-20051780</secondary_id>
    <secondary_id>ONCOTHER-424Sm35</secondary_id>
    <secondary_id>CYTOGEN-ONCOTHER-20051780</secondary_id>
    <nct_id>NCT00316940</nct_id>
  </id_info>
  <brief_title>Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase I Study of Samarium Sm-153 Lexidronam Combined With Bortezomib for Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radioactive substances, such as samarium 153, may release radiation as it breaks&#xD;
      down and kill cancer cells. Bortezomib may stop the growth of cancer cells by blocking some&#xD;
      of the enzymes needed for cell growth. Bortezomib may also make tumor cells more sensitive to&#xD;
      radiation. Giving samarium 153 together with bortezomib may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of samarium 153 when&#xD;
      given together with bortezomib in treating patients with relapsed or refractory multiple&#xD;
      myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Assess the safety and tolerability (maximum tolerated dose and dose-limiting toxicity)&#xD;
           of samarium Sm 153 lexidronam pentasodium and bortezomib in patients with relapsed or&#xD;
           refractory multiple myeloma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response rate (combined complete response, partial response, and minimal&#xD;
           response) in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the time to response and the time to progression of disease in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the progression-free survival and overall survival of patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Assess the antitumor effects of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of samarium Sm 153 lexidronam&#xD;
      pentasodium.&#xD;
&#xD;
      Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and samarium Sm 153&#xD;
      lexidronam pentasodium IV on day 3. Treatment repeats every 8 weeks for up to 4 courses in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of samarium Sm 153 lexidronam pentasodium&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 6 patients experience dose-limiting toxicity. The MTD of&#xD;
      samarium Sm 153 lexidronam pentasodium is determined with 2 different doses of bortezomib.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose and dose-limiting toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (complete, partial, and minimal response)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression and time to response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free and overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor effects</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>samarium Sm 153 lexidronam pentasodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosed with multiple myeloma by 1 of the following criteria:&#xD;
&#xD;
               -  Meets any 2 of the following major criteria:&#xD;
&#xD;
                    -  Plasmacytomas on tissue biopsy&#xD;
&#xD;
                    -  Bone marrow plasmacytosis (i.e., &gt; 30% plasma cells)&#xD;
&#xD;
                    -  Monoclonal immunoglobulin spike IgG &gt; 3.5 g/dL or IgA &gt; 2.0 g/dL by serum&#xD;
                       electrophoresis; kappa or lambda light chain excretion &gt; 1 g by 24-hour&#xD;
                       urine protein electrophoresis&#xD;
&#xD;
               -  Plasmacytomas on tissue biopsy AND meets any 1 of the following minor criteria:&#xD;
&#xD;
                    -  Presence of monoclonal immunoglobulin at a lesser magnitude than given under&#xD;
                       above major criteria&#xD;
&#xD;
                    -  Lytic bone lesions&#xD;
&#xD;
                    -  Normal IgM &lt; 50 mg/dL, IgA &lt; 100 mg/dL, or IgG &lt; 600 mg/dL&#xD;
&#xD;
               -  Monoclonal immunoglobulin spike IgG &gt; 3.5 g/dL or IgA &gt; 2.0 g/dL by serum&#xD;
                  electrophoresis; kappa or lambda light chain excretion &gt; 1 g by 24-hour urine&#xD;
                  protein electrophoresis AND meets 1 of the following minor criteria:&#xD;
&#xD;
                    -  Bone marrow plasmacytosis (i.e., 10-30% plasma cells)&#xD;
&#xD;
                    -  Lytic bone lesions&#xD;
&#xD;
               -  Presence of monoclonal immunoglobulin at a lesser magnitude than given under&#xD;
                  major criteria with bone marrow plasmacytosis (i.e., 10-30% plasma cells) AND&#xD;
                  meets 1 of the following minor criteria:&#xD;
&#xD;
                    -  Lytic bone lesions&#xD;
&#xD;
                    -  Normal IgM &lt; 50 mg/dL, IgA &lt; 100 mg/dL, or IgG &lt; 600 mg/dL&#xD;
&#xD;
          -  Measurable disease, defined as a monoclonal immunoglobulin spike of ≥ 1 gm/dL by serum&#xD;
             electrophoresis and/or a immunoglobulin spike of ≥ 200 mg by 24-hour urine protein&#xD;
             electrophoresis or evidence of lytic bone disease OR&#xD;
&#xD;
          -  Nonmeasurable disease (i.e., patients with nonsecretory or oligosecretory multiple&#xD;
             myeloma)&#xD;
&#xD;
          -  Relapsed or refractory disease&#xD;
&#xD;
               -  Relapsed disease following a response or stable disease after prior chemotherapy&#xD;
                  (e.g., single-agent steroids, vincristine, doxorubicin, and dexamethasone [VAD],&#xD;
                  or melphalan and prednisone [MP]) or high-dose chemotherapy&#xD;
&#xD;
               -  Refractory (i.e., failure to achieve at least complete or partial response or&#xD;
                  stable disease) to the most recent chemotherapy with or without systemic&#xD;
                  corticosteroids&#xD;
&#xD;
          -  No plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal&#xD;
             protein (M-protein), and skin changes (POEMS syndrome)&#xD;
&#xD;
          -  No extramedullary myeloma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm³&#xD;
&#xD;
          -  AST and ALT ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 2 times ULN (unless clearly related to disease)&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
               -  Creatinine clearance &gt; 15 mL/min and &lt; 30 mL/min due to significant myelomatous&#xD;
                  involvement of kidneys allowed at discretion of investigator&#xD;
&#xD;
          -  Sodium &gt; 130 mmol/L&#xD;
&#xD;
          -  No ECG evidence of acute ischemia or new conduction system abnormalities&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No severe hypercalcemia (i.e., serum calcium ≥ 14 mg/dL)&#xD;
&#xD;
          -  No New York Hospital Association class III or IV heart failure&#xD;
&#xD;
          -  No poorly controlled hypertension, diabetes mellitus, or other serious medical or&#xD;
             psychiatric illness that would preclude study treatment&#xD;
&#xD;
          -  No known HIV history&#xD;
&#xD;
          -  No known active hepatitis B or C viral infection&#xD;
&#xD;
          -  No history of allergic reaction attributable to compounds of similar chemical or&#xD;
             biological composition to bortezomib, boron, mannitol,&#xD;
             ethylenediaminetetramethylenephosphonic acid (EDTMP), or phosphonates&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 12 weeks since prior samarium Sm 153 lexidronam pentasodium&#xD;
&#xD;
               -  No more than 1 prior treatment&#xD;
&#xD;
          -  At least 24 weeks since prior strontium chloride Sr 89&#xD;
&#xD;
               -  No more than 1 prior treatment&#xD;
&#xD;
          -  No major surgery within the past 4 weeks&#xD;
&#xD;
          -  No chemotherapy within the past 3 weeks (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  No corticosteroids (&gt; 10 mg/day prednisone or equivalent) within the past 3 weeks&#xD;
&#xD;
          -  No immunotherapy, antibody therapy, or radiotherapy (except localized radiotherapy)&#xD;
             within the past 4 weeks&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent corticosteroids (≥ 10 mg prednisone or equivalent)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James R. Berenson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncotherapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309-0633</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Medical Group of Fresno, Incorporated</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders at Suburban Hospital</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Y, Mapes R, Abaya CD, Swift RA. A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 2009 Feb 1;15(3):1069-75. doi: 10.1158/1078-0432.CCR-08-1261.</citation>
    <PMID>19188182</PMID>
  </results_reference>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>April 19, 2006</study_first_submitted>
  <study_first_submitted_qc>April 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2006</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Samarium Sm-153 lexidronam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

